Venous thromboembolism and cyproterone acetate in men with prostate cancer: a study using the General Practice Research Database

Seaman, Helen E.; Langley, Stephen; Farmer, Richard; Vries, Corinne S de

doi:10.1111/j.1464-410x.2007.06859.x

Cited by 20 publications

(12 citation statements)

References 24 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Seaman et al compared the risk of venous thromboembolism among patients treated with different antiandrogens and LHRH agonists. The group found that venous thromboembolism was associated only with cyproterone acetate, whereas the other antiandrogens did not contribute to thromboembolic event 17. In our series, ADT users presented a significantly higher percentage of lower leg fracture/surgery than the non-ADT users (6.30% vs 5.27%, p<0.01).…”

Section: Discussioncontrasting

confidence: 46%

Association between ischaemic bowel syndromes and androgen deprivation therapy in patients with prostate cancer: a retrospective cohort study

Chiang

Huang

et al. 2017

BMJ Open

View full text Add to dashboard Cite

ObjectiveThis study investigated the risk of ischaemic bowel syndrome (IBS) in androgen deprivation therapy (ADT) users to explore the long-term outcomes of patients with prostate cancer (PC) receiving ADT treatment.MethodsWe performed a population-based retrospective cohort study. All the clinical information of the study participants were acquired from the Longitudinal Health Insurance Database for Catastrophic Illness Patients in Taiwan. We extracted data for all the patients newly diagnosed with prostate malignancy (ICD-9-CM 185 or C61 in ICD-10-CM) from 2000 to 2008. The patients were then divided into two groups: 7160 male ADT cohort receiving ADT and 7160 male non-ADT comparison group frequency matched by age and index year of ADT treatment of the ADT group. Cox proportional hazard regression was used to estimate the adjusted HR and 95% CIs of the IBS risk.ResultsNo significant difference was noted in the overall incidence rate for IBS between the ADT and non-ADT cohorts (0.86 and 0.89 per 1000 person–year, respectively, p=0.89). Even after adjusting for potential risk factors, a 1.06-fold risk of IBS (95% CI 0.62 to 1.82, p=0.82) was observed in the ADT cohort relative to the non-ADT cohorts. Moreover, we stratified the ADT cohort by time point of ADT treatment after PC diagnosis. Different IBS incidence rates were observed among the early ADT, late-ADT and non-ADT users at 0.77, 1.23 and 0.89 per 1000 person-years, respectively; nonetheless, the difference was not statistically significant. Moreover, no difference was found between the ADT treatment types and IBS risk, including sole orchiectomy, sole luteinising-hormone-releasing hormone and both.ConclusionsResults showed that ADT treatment in patients with PC is not an independent factor for IBS incidence. Large sample sizes for patients with IBS with patients with PC who had received ADT treatment are needed for further study.

show abstract

Section: Discussioncontrasting

confidence: 46%

Association between ischaemic bowel syndromes and androgen deprivation therapy in patients with prostate cancer: a retrospective cohort study

Chiang

Huang

et al. 2017

BMJ Open

View full text Add to dashboard Cite

show abstract

“…The aim of internal validation is to separate uncertain from true cases based on information from Lungenembolie). Um in der GPRD Patienten mit dem bestätigten akuten Ereignis von anderen Patienten abgrenzen zu kön-nen, d. h. also zur Diagnosesicherung, wurde in mehreren Arbeiten neben der geführten Diagnose als zusätzliches Kriterium das Vorliegen einer Coumarin-Verschreibung genutzt [10,11,12]. Problematisch kann ein solches Vorgehen aber dann sein, wenn ein akutes Ereignis gehäuft zu letalen Verläufen führt: Hier würde dann eine ambulante Verschreibung des Zielarzneimittels natürlich nicht mehr erfolgen, das zusätzliche Kriterium in der Datenbank also nicht mehr erscheinen.…”

Section: Validation Of Secondary Data Strengths and Limitations Abstunclassified

“…Um diesem Problem zu begegnen, haben einige Autoren z. B. bei venösen thromboembolischen Ereignissen als Einschlusskriterium auch den Tod aufgrund eines solchen Ereignisses in ihre Falldefinition aufgenommen [10,11] oder alternativ zur Coumarin-Verschreibung als Zusatzkriterium eine verzeichnete Hospitalisierung gefordert [12].…”

Section: Validation Of Secondary Data Strengths and Limitations Abstunclassified

Validierung von Sekundärdaten

Hoffmann

Andersohn

Giersiepen

et al. 2008

Bundesgesundheitsbl.

View full text Add to dashboard Cite

Medical records databases (such as the General Practice Research Database-GPRD) and administrative databases (such as German Statutory Health Insurance (SHI) claims data) are useful sources for pharmacoepidemiology and health services research. However, these data are not primarily collected for research purposes. Validation studies are needed to examine their completeness and accuracy depending on the corresponding research question. This article reviews strategies for checks of internal consistency within the data from one SHI as well as between data from several SHIs and possibilities of internal data validation. Descriptive analyses of consistency can help to determine the integrity of data. The aim of internal validation is to separate uncertain from true cases based on information from secondary data alone or to reproduce known associations within the database. In addition external validation of secondary data is desirable using original prescriptions, medical records, hospital discharge letters and/or patient or physician interviews as a gold standard. A considerable number of external validation studies of diagnostic coding have been conducted within the GPRD. In contrast, such validation studies of German SHI claims data are mostly lacking and are urgently needed in the near future.

show abstract

“…VTE occurred more frequently in breast cancer patients randomized to tamoxifen than in those on placebo, anastrozole, or exemestane, respectively, and the incidence of ATE was higher for tamoxifen than that of either anastrozole or letrozole [42][43][44][45][46][47][48]. That noted, a metaanalysis calculated the absolute excess incidence of DVT, PE, and CVA in tamoxifen-treated patients as only 0.037%, 0.038%, and 0.267%, respectively [43].…”

Section: Treatment Factorsmentioning

confidence: 99%

“…In a study of palliative cyproterone acetate (CPA), LHRH analogs, estrogen, and non-steroidal antiandrogens for prostate cancer, VTE was a hazard with all of these agents. However, CPA was significantly more thrombogenic than anti-androgens (OR 3.46; 95% CI: 1.91-6.25) or LHRH analogs (OR 3.35; 95% CI: 2.38-4.72) [48].…”

Section: Treatment Factorsmentioning

confidence: 99%

Thrombophilic state in cancer, Part I: Biology, incidence, and risk factors

DiPasco

Misra

Koniaris

et al. 2011

Journal of Surgical Oncology

View full text Add to dashboard Cite

The association between malignancy and thrombosis has long been appreciated but remains incompletely understood. This is the first of a two-part review of the complex, integral relationship between these two entities, and addresses the mechanisms and pathogenesis of this relationship and the clinical risk factors for thromboembolism in cancer patients.J. Surg. Oncol. 2011;104:316-322. ß 2011 Wiley-Liss, Inc.KEY WORDS: thromboembolism; cancer biology; thrombophilic state; risk factorsThe association of thrombophilia with cancer has long been recognized. In 1868, Trousseau described this in presenting a series of patients with gastrointestinal neoplasms to the New Sydenham Society in London. In 1878, Theodor Billroth lectured on his observation of cancer cells within intravascular thrombi to the same Society, postulating that distant metastasis of cancer occurs primarily through venous thromboembolism (VTE) [1,2]. Rudolf Virchow made the seminal observation of the association of stasis, hypercoagulability, and endothelial damage in VTE. Morrison [3] was the first to report specific prothrombotic humoral abnormalities in cancer patients, publishing his findings in 1932.The clinical incidence of VTE in cancer patients ranges from 10% to 20%. The incidence in autopsy series exceeds 50%, with pulmonary embolism being present in 26% (range 13-42%). The clinical incidence of VTE in cancer patients is roughly fourfold higher than that in those with non-malignant diagnoses [4,5].The prevalence of malignancy among all patients with VTE ranges from 4% to 20%. There is a 4-to 5-fold increase in postoperative VTE in cancer patients as compared to patients with other diagnoses undergoing the same surgical procedures. VTE remains the second commonest proximate cause of death in cancer patients overall [6][7][8][9]. This is the first part of a two-part review of the thrombophilic state in cancer. The focus of this part is on the biochemical and clinical prevalence of hemostatic derangements in cancer, their role in cancer biology, and risk factors for thromboembolism in cancer patients. The second part will address thromboembolism and cancer outcomes, anticoagulation and cancer outcomes, suppression and prevention, VTE and occult malignancy, and progress in antithrombotic therapy, and possibilities in future cancer treatment.

show abstract

Venous thromboembolism and cyproterone acetate in men with prostate cancer: a study using the General Practice Research Database

Cited by 20 publications

References 24 publications

Association between ischaemic bowel syndromes and androgen deprivation therapy in patients with prostate cancer: a retrospective cohort study

Association between ischaemic bowel syndromes and androgen deprivation therapy in patients with prostate cancer: a retrospective cohort study

Validierung von Sekundärdaten

Thrombophilic state in cancer, Part I: Biology, incidence, and risk factors

Contact Info

Product

Resources

About